Related Experiment Video
Updated: Dec 9, 2025
Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells
Published on: February 14, 2025
Novel cellular immunotherapy using NKG2D CAR-T for the treatment of cervical cancer
Yan Zhang1, Xing Li1, Jun Zhang1
1Department of Obstetrics and Gynecology, Renmin Hospital of Wuhan University, Wuhan, China.
Abstract:
Cellular immunotherapy, including chimeric antigen receptor (CAR) modified T cell therapy, has been regarded as one of the most potential antineoplastic drugs for hematological malignancies and solid tumor. However, due to lacking the suitable target, there is no CAR-T drug had been appoved by FDA for the treatment of cervical cancer, one of the most malignant cancers for women. In current study, we designed a NKG2D CAR-T targeting NKG2DL. The NKG2D CAR-T exhibited high-efficient anti-tumor capacity for NKG2DL positive cervical cancer cell line in vitro. In addition, the amount of cytokines secreted from CAR-T cells have had significantly enhanced after co-cultured with NKG2DL positive tumor cell in vitro. In vivo, NKG2D CAR-T cells presented a robust capacity of significantly suppressing tumor growth. Moreover, there was no obvious off-target toxicity after NKG2D CAR-T infusion. Taken together, NKG2D CAR-T showed excellent therapy effect for cervical cancer and might be used as a novel cellular therapeutic agent for treating cervical cancer.
Insights
New chimeric antigen receptor T-cell (CAR-T) therapy targets NKG2DL, showing potent anti-cancer effects against cervical cancer in preclinical studies with no observed toxicity.
Area of Science:
- Immunology
- Oncology
- Biotechnology
Background:
- Chimeric antigen receptor (CAR) T-cell therapy is a promising cancer treatment, but lacks FDA-approved options for cervical cancer due to target limitations.
- Cervical cancer remains a significant threat to women's health, necessitating novel therapeutic strategies.
Purpose of the Study:
- To develop and evaluate a novel NKG2D-ligand (NKG2DL)-targeted CAR-T cell therapy for cervical cancer.
- To assess the efficacy and safety of NKG2D CAR-T cells in preclinical models of cervical cancer.
Main Methods:
- Design and construction of NKG2D CAR-T cells targeting NKG2DL.
- In vitro evaluation of anti-tumor activity and cytokine secretion against NKG2DL-positive cervical cancer cells.
- In vivo assessment of tumor growth suppression and off-target toxicity in preclinical cervical cancer models.
Main Results:
- NKG2D CAR-T cells demonstrated potent in vitro anti-tumor activity against NKG2DL-positive cervical cancer cell lines.
- Co-culture with tumor cells significantly enhanced cytokine secretion from NKG2D CAR-T cells.
- In vivo studies showed robust tumor growth suppression by NKG2D CAR-T cells with no apparent off-target toxicity.
Conclusions:
- NKG2D CAR-T cell therapy exhibits significant therapeutic potential for cervical cancer.
- This novel approach may serve as a promising cellular therapeutic agent for treating cervical cancer.
More Related Videos
Related Concept Videos
01:27Tumor Immunotherapy
01:27Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...